RA
EBS icon

Royce & Associates’s Emergent Biosolutions EBS Stock Holding History

Royce & Associates’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-178,676
Closed -$7.34M – 948
2022
Q1 		$7.34M Buy
178,676
+2,120
+1% +$93.5K 0.06% 456
2021
Q4 		$7.67M Sell
176,556
-59,275
-25% -$2.68M 0.06% 461
2021
Q3 		$11.8M Buy
235,831
+941
+0.4% +$57K 0.09% 358
2021
Q2 		$14.8M Sell
234,890
-2,271
-1% -$146K 0.1% 337
2021
Q1 		$22M Buy
237,161
+53,579
+29% +$5.49M 0.15% 218
2020
Q4 		$16.4M Buy
183,582
+68,017
+59% +$6.24M 0.14% 227
2020
Q3 		$11.9M Sell
115,565
-63,429
-35% -$6.84M 0.13% 234
2020
Q2 		$14.2M Sell
178,994
-22,000
-11% -$1.64M 0.16% 176
2020
Q1 		$11.6M Sell
200,994
-115,933
-37% -$6.68M 0.16% 176
2019
Q4 		$17.1M Buy
316,927
+17,419
+6% +$945K 0.15% 179
2019
Q3 		$15.7M Buy
299,508
+58,644
+24% +$2.73M 0.14% 200
2019
Q2 		$11.6M Buy
240,864
+235,230
+4,175% +$11.3M 0.11% 281
2019
Q1 		$285K Buy
+5,634
New +$332K ﹤0.01% 973
2018
Q4 		– Sell
-559
Closed -$37K – 1164
2018
Q3 		$37K Buy
559
+195
+54% +$11.4K ﹤0.01% 1067
2018
Q2 		$18K Buy
364
+152
+72% +$7.92K ﹤0.01% 1140
2018
Q1 		$11K Sell
212
-20
-9% -$997 ﹤0.01% 1162
2017
Q4 		$11K Sell
232
-26
-10% -$1.09K ﹤0.01% 1165
2017
Q3 		$10K Buy
+258
New +$9.34K ﹤0.01% 1163
2013
Q3 		– Sell
-30,386
Closed -$438K – 1453
2013
Q2 		$438K Buy
+30,386
New +$440K ﹤0.01% 1244

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royce & Associates's EBS Position: Q2 2022 in Review

Royce & Associates sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 178,676 shares — an estimated $7.34M sold.

Royce & Associates first reported a position in EBS in Q2 2013 and held it in 19 quarters. The position peaked at $22M in Q1 2021. 231 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

  • Royce & Associates reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
  • Royce & Associates sold 178,676 Emergent Biosolutions shares in Q2 2022, an estimated $7.34M.
  • Royce & Associates first reported a position in Emergent Biosolutions in Q2 2013 and held it in 19 quarters.
  • Royce & Associates's Emergent Biosolutions position peaked at $22M in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Royce & Associates's 13F filing for Q2 2022, filed 4 Aug 2022.